This brand name is authorized in Israel, United States
The drug FANAPT contains one active pharmaceutical ingredient (API):
|
1
Iloperidone
UNII VPO7KJ050N - ILOPERIDONE
|
|
The mechanism of action of iloperidone in schizophrenia and bipolar I disorder is unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| FANAPT Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IL | מִשְׂרַד הַבְּרִיאוּת | Identifier(s): 6942, 6943, 6944, 6945, 6946, 7155, 7156, 7252 |
| Country: US | FDA, National Drug Code | Identifier(s): 43068-101, 43068-102, 43068-104, 43068-106, 43068-108, 43068-110, 43068-112, 43068-901, 43068-902, 70518-1867 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
